-+ 0.00%
-+ 0.00%
-+ 0.00%

Curocell Secures South Korean Approval to Amend Phase 1/2 Trial of CRC01 in Adult Leukemia

PUBT·11/18/2026 10:44:04
Diffusion vocale
Curocell Secures South Korean Approval to Amend Phase 1/2 Trial of CRC01 in Adult Leukemia
  • Curocell received South Korean regulatory clearance on Nov. 18, 2026, to amend its CRC01 trial in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
  • The amendment separates the leukemia trial protocol following marketing authorization for relapsed or refractory diffuse large B-cell lymphoma, enabling independent trial operations.
  • The Phase 1/2 study will evaluate CRC01’s tolerability, safety and efficacy, with completion expected Sept. 30, 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curocell Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261118900627), on November 18, 2026, and is solely responsible for the information contained therein.